Pharmaceutical Executive-01-01-2018

In our annual temperature check on the life sciences sector and its outlook for the months ahead, we explore eight trends that will shape the biopharma industry landscape in 2018.

Bruno Strigini, CEO of Novartis Oncology, talks about the company’s pioneering path in cancer-starting with Gleveec and continuing with last year’s approval of the first-ever CAR-T cell therapy-touching on the related broader issues such as pricing and value and new innovations in cancer science.

States will continue to press for price controls, while FDA will tackle opioids and promote innovation.

The advent of immunocellular therapies marks a major milestone in pharma, but the path for these treatments in transforming patient care is still forming as they face challenges in clinical trials, pricing, and market acceptance,

Five predictions on evolution of data and predictive insights that could be critical for pharma go-to-market strategies.

Program puts a new-and very real-spin on patient nutrition.

Is getting more clarity on Brexit ramifications for pharma and European public health really at the top of new-year to-do lists?

Three pivotal developments that occurred in 2017 illustrate the growing relevance and influence of the Swiss pharmaceutical and life sciences industry on the world stage. Companies in Switzerland are also playing innovative roles in reshaping the pharma value chain and contemporary paradigm of healthcare provision.

Click the title above to open the Pharmaceutical Executive January 2018 issue in an interactive PDF format.